|By Marketwired .||
|February 7, 2013 01:47 AM EST||
BASEL, SWITZERLAND -- (Marketwire) -- 02/07/13 --
Basilea Pharmaceutica AG / Basilea reports 2012 financials with a solid cash position and significant milestones ahead . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.
* CFO Joachim Blatter to depart company, CEO Ronald Scott to serve as interim CFO
* Cash position and short-term investments increased to CHF 344.0 million
* Target patient recruitment reached in two isavuconazole phase 3 studies with data expected in H2 2013
* European regulatory review of ceftobiprole in pneumonia ongoing with first potential approval in Q4 2013
* Toctino® agreement with potential U.S. filing by Stiefel early 2014
Basilea Pharmaceutica Ltd. (SIX: BSLN) presented today full-year financial results for 2012 with an increased year-end cash position of CHF 344.0 million and a reduced net loss of CHF 53.0 million. CFO Joachim Blatter will be leaving the company to pursue other opportunities. Ronald Scott, CEO will serve as interim CFO effective February 7, 2013.
2012 was a transformational year. Basilea took the strategic decision to focus its activities on anti-infective and oncology drugs and entered into an agreement for its dermatology drug Toctino® (alitretinoin) with Stiefel, a GSK company, for a CHF 224.1 million initial payment and additional potential payments related to the commercialization of Toctino® in the U.S. Stiefel has assumed responsibility for the development, manufacturing and commercialization of Toctino®. Basilea is eligible for a further milestone payment related to the launch of alitretinoin in the U.S. and will participate in future U.S. product sales. Toctino® 2012 sales through completion of the Stiefel agreement were CHF 20.2 million, in line with the company's guidance.
In 2012, Basilea advanced the isavuconazole phase 3 program in collaboration with Astellas and filed a ceftobiprole Marketing Authorization Application submission for severe pneumonia in Europe. In addition, Basilea completed its U.S. phase 3 study for alitretinoin.
The isavuconazole SECURE phase 3 registration study, evaluating safety and efficacy of once-daily isavuconazole versus twice-daily voriconazole for the primary treatment of life-threatening invasive fungal disease caused by Aspergillus species completed patient recruitment. In addition, enrollment into the isavuconazole VITAL study, an open-label phase 3 study in the treatment of aspergillosis patients with pre-existing renal impairment or with invasive fungal disease caused by rare but often fatal molds, has achieved its initially targeted recruitment of patients. Enrollment will continue to further expand the database on the use of isavuconazole in the primary treatment of diverse rare mold infections. Topline data from these two isavuconazole phase 3 studies are expected in the second half of 2013 and could result in a first potential filing in the first quarter of 2014. Under the agreement with Astellas, Basilea is eligible for milestone payments related to filing, approval and sales, and double-digit royalty payments. Furthermore, Basilea retains co-promotion rights on the drug and will evaluate these rights as the drug comes closer to the market. The isavuconazole ACTIVE phase 3 study, evaluating the use of isavuconazole i.v. and oral versus caspofungin i.v. followed by oral voriconazole for the treatment of invasive Candida infections, will likely continue to recruit into 2014. Basilea and its partner Astellas are reviewing potential filing strategies including a first filing of the SECURE and VITAL studies.
In 2012, Basilea also focused on bringing ceftobiprole to the market, initially for patients with severe lung infections. Basilea submitted a Marketing Authorization Application in Europe for the treatment of pneumonia which was accepted for review in October 2012. Currently the company focuses on answering the questions received from the European agencies. Basilea had a consultation meeting with the FDA in 2012 and will continue its discussions with the FDA to receive the agency's final recommendation on the indications that could potentially be supported by the existing data package. The FDA requested that Basilea conduct further analyses of the existing phase 3 dataset to assist FDA in developing a final recommendation. A follow-up consultation meeting for a discussion of the data is envisaged in the second quarter of 2013. Basilea is managing the ceftobiprole supply chain to support a potential regulatory approval and launch and is engaged in discussions with potential partners.
Basilea's commitment to address the medical challenge of resistance in the areas of anti-infectives and oncology is also reflected in its phase 1 programs with innovative compounds from in-house research, addressing high medical needs in these focus areas. The novel antibiotic BAL30072 is intended for the treatment of multidrug-resistant Gram-negative bacteria where current antibiotics often fail, and the new oncology drug BAL101553 focuses on the treatment of tumors resistant to current cancer therapies. Basilea made substantial progress during 2012 in advancing these compounds in clinical phase 1 development. BAL30072 moved into its next stage of phase 1 testing and BAL101553 is anticipated to move into phase 2a studies in 2013.
Ronald Scott, CEO stated: "We made significant achievements in 2012. Through the Toctino transaction we improved our cash position and we will continue to prudently invest our resources to achieve our key value-driving events. Now we are focused on our important milestones for 2013, including the potential approval of ceftobiprole in Europe and first anticipated isavuconazole phase 3 topline data." He added: "Basilea is uniquely positioned through our innovative drug portfolio to address the increasing threat posed by multi-drug resistant infections and drug resistant cancers for which there are currently limited treatments available. The critical need to address drug resistance is gaining increasing awareness. Recent measures taken by several countries further encourage the development of novel antibiotics and antifungals for the treatment of drug-resistant life-threatening infections by providing potential benefits that could result in shorter development and regulatory timelines and longer market exclusivity." Related to the departure of Joachim Blatter he said: "We want to thank Joachim for his contributions, and wish him all the best for his new endeavors."
+-----------------------------------------------------+---------+---------+ | (In CHF million, except per share data) | 2012 | 2011 | +-----------------------------------------------------+---------+---------+ | Product sales* | 20.2 | 31.0 | +-----------------------------------------------------+---------+---------+ | Contract revenue | 37.4 | 35.2 | +-----------------------------------------------------+---------+---------+ | Revenue from R&D services | 0.2 | 0.6 | +-----------------------------------------------------+---------+---------+ | Other income | 0.5 | 0.2 | +-----------------------------------------------------+---------+---------+ | Total operating income | 58.3 | 66.8 | +-----------------------------------------------------+---------+---------+ | Cost of sales | (4.4) | (2.4) | +-----------------------------------------------------+---------+---------+ | Research & development expenses | (58.9) | (70.0) | +-----------------------------------------------------+---------+---------+ | Selling*, general & administrative expenses | (45.9) | (51.7) | +-----------------------------------------------------+---------+---------+ | Total operating expenses | (109.2) | (124.1) | +-----------------------------------------------------+---------+---------+ | Operating loss | (50.8) | (57.3) | +-----------------------------------------------------+---------+---------+ | Net loss | (53.0) | (57.6) | +-----------------------------------------------------+---------+---------+ | Net cash provided by/used for operating activities | 148.2 | (82.4) | +-----------------------------------------------------+---------+---------+ | Cash and short-term investments | 344.0 | 197.1 | +-----------------------------------------------------+---------+---------+ | Basic and diluted loss per share, in CHF | (5.53) | (6.01) | +-----------------------------------------------------+---------+---------+
Notes: Consolidated figures in conformity with US GAAP; rounding was consistently applied.
*2012 numbers: Through July.
The consolidated financial statements of Basilea Pharmaceutica Ltd. for 2012 can be found on the company's website at http://annualreport.basilea.com.
Product sales in 2012 for Toctino® were within guidance amounting to CHF 20.2 million, through July 2012, when the Stiefel transaction closed (full-year 2011: CHF 31.0 million).
Contract revenue in 2012 amounted to CHF 37.4 million (2011: CHF 35.2 million), including CHF 16.1 million related to the agreement with Stiefel on Toctino®, CHF 12.8 million related to Toctino® distribution agreements and CHF 8.2 million related to the license agreement with Astellas for isavuconazole. Total operating income decreased to CHF 58.3 million in 2012 (2011: CHF 66.8 million) primarily due to the shorter product sales period as a result of the agreement with Stiefel on Toctino® in July 2012.
Research and development expenses amounted to CHF 58.9 million in 2012, compared to CHF 70.0 million in 2011. This decrease is mainly due to the completion of the alitretinoin phase 3 U.S. study in the first half of 2012 and Basilea fulfilling its financial participation commitment in the development of isavuconazole under the license agreement with Astellas. Selling, general and administrative expenses decreased to CHF 45.9 million in 2012 (2011: CHF 51.7 million) primarily due to closing Basilea's commercial organizations following its Toctino® agreement with Stiefel in the second half of 2012.
In 2012, the operating loss decreased to CHF 50.8 million from CHF 57.3 million in 2011, mainly due to lower research and development costs as well as lower selling, general and administrative expenses. As a result of this, the average monthly operating loss for 2012 was CHF 4.2 million. The net loss 2012 amounted to CHF 53.0 million, compared to CHF 57.6 million in 2011.
2012 basic and diluted loss per share amounted to CHF 5.53 compared to basic and diluted loss per share of CHF 6.01 in 2011.
In 2012, the net cash provided by operating activities was CHF 148.2 million as compared to net cash used by operating activities of CHF 82.4 million in 2011, mainly due to the upfront payment of CHF 224.1 million received from Stiefel for the Toctino® agreement. Combined cash and short-term investments increased to CHF 344.0 million as of December 31, 2012, compared to CHF 197.1 million at year-end 2011.
Total operating expenses for 2013 are estimated to decrease to around CHF 7 to 8 million per month primarily due to the Toctino® transaction and Basilea having fulfilled in 2012 its financial participation commitment related to the development of isavuconazole. Basilea's average operating loss in 2013 is estimated at around CHF 4 to 5 million per month.
Isavuconazole - a novel intravenous and oral broad-spectrum antifungal, partnered with Astellas Pharma Inc., for the potential treatment of severe invasive and life-threatening fungal infections
Isavuconazole demonstrated excellent in-vitro and in-vivo coverage of a broad range of yeasts (such as Candida species) and molds (such as Aspergillus species) as well as in-vitro activity against less prevalent but often fatal molds such as Mucorales spp. It has U.S. FDA fast-track status. In clinical studies to date it achieved predictable drug levels and high oral bioavailability suggesting the potential for predictable dosing and a switch from i.v. administration to convenient once-daily oral dosing.
Ceftobiprole - a novel broad-spectrum antibiotic for the potential first-line empiric treatment of severe multidrug-resistant bacterial infections
Ceftobiprole has unique broad-spectrum activity against Gram-positive bacteria, including methicillin-resistant and vancomycin-resistant Staphylococcus aureus (MRSA, VRSA) and penicillin-resistant Streptococcus pneumoniae (PRSP) as well as Gram-negative pathogens, including Enterobacteriaceae and Pseudomonas aeruginosa. Ceftobiprole has met the study endpoints in several phase III studies and has shown a typical cephalosporin safety profile.
BAL30072 - a novel innovative sulfactam antibiotic with bactericidal activity against multidrug-resistant Gram-negative bacteria
The investigational drug has demonstrated broad in-vitro and in-vivo coverage of Gram-negative pathogens including multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. It has robust activity against common strains of bacteria that produce antibiotic-inactivating enzymes including extended-spectrum beta-lactamases (ESBL) and metallo-beta-lactamases such as the New Delhi metallo-beta-lactamase 1 (NDM-1). In addition, BAL30072 has been shown to enhance the activity of antibiotics from the penem class.
BAL101553 - a novel small-molecule anti-cancer drug with a dual mode of action directly attacking tumor cells as well as disrupting tumor blood vessels
BAL101553 disrupts the intracellular microtubule network that is essential for cell division and has shown potent activity in many tumor cell lines that are insensitive or resistant to taxanes or other microtubule-targeting agents. In contrast to currently available microtubule-targeting agents that are derived from complex natural products, BAL101553 is a simpler synthetic molecule that bypasses some of the resistance mechanisms associated with existing drugs. BAL101553 was developed as a highly water-soluble prodrug of Basilea's BAL27862 with anticipated good oral bioavailability and an injectable formulation without potentially harmful solubilizers.
Toctino® (oral alitretinoin) - the only licensed drug for systemic use in adults with severe chronic hand eczema unresponsive to potent topical corticosteroids
Toctino® was developed and successfully brought to market by Basilea. In the U.S., oral alitretinoin is an investigational drug in phase III and not yet approved by the FDA. In July 2012, Basilea completed an agreement for Toctino® with Stiefel, a GSK company.
Basilea Pharmaceutica Ltd. invites you to participate in a conference call on Thursday, February 7, 2013, 4 p.m. (CET), during which the company will discuss today's press release.
Dial-in numbers are:
+41 (0) 91 610 56 00 (Europe and ROW) +1 (1) 866 291 4166 (USA) +44 (0) 203 059 5862 (UK)
A playback will be available 1 hour after the conference call until Monday, February 11, 2013, 6 p.m. (CET). Participants requesting a digital playback may dial:
+41 (0) 91 612 4330 (Europe and ROW) +1 (1) 866 416 2558 (USA) +44 (0) 207 108 6233 (UK)
and will be asked to enter the ID 18060 followed by the # sign.
Note to shareholders
The shareholders of Basilea Pharmaceutica Ltd. are informed that the Ordinary General Meeting of Shareholders of Basilea Pharmaceutica Ltd. will take place on Tuesday, April 9, 2013 at 2 p.m. at the Hilton Hotel in Basel, Switzerland. The invitation will be published in the Swiss Official Gazette of Commerce (Schweizerisches Handelsamtsblatt, SHAB). Shareholders who are recorded in the share register with voting rights on March 28, 2013 will be entitled to participate and exercise their voting rights.
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Through the fully integrated research and development operations of its Swiss subsidiary Basilea Pharmaceutica International Ltd., the company focuses on innovative pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology, targeting the medical challenge of rising resistance and non-response to current treatment options.
This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
This press release can be downloaded from www.basilea.com.
Press Release (PDF):
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Basilea Pharmaceutica AG via Thomson Reuters ONE
In his session at @ThingsExpo, Tony Shan, Chief Architect at CTS, will explore the synergy of Big Data and IoT. First he will take a closer look at the Internet of Things and Big Data individually, in terms of what, which, why, where, when, who, how and how much. Then he will explore the relationship between IoT and Big Data. Specifically, he will drill down to how the 4Vs aspects intersect with IoT: Volume, Variety, Velocity and Value. In turn, Tony will analyze how the key components of IoT influence Big Data: Device, Connectivity, Context, and Intelligence. He will dive deep to the matrix...
Oct. 6, 2015 06:00 PM EDT Reads: 302
When it comes to IoT in the enterprise, namely the commercial building and hospitality markets, a benefit not getting the attention it deserves is energy efficiency, and IoT’s direct impact on a cleaner, greener environment when installed in smart buildings. Until now clean technology was offered piecemeal and led with point solutions that require significant systems integration to orchestrate and deploy. There didn't exist a 'top down' approach that can manage and monitor the way a Smart Building actually breathes - immediately flagging overheating in a closet or over cooling in unoccupied ho...
Oct. 6, 2015 05:00 PM EDT Reads: 245
Scott Guthrie's keynote presentation "Journey to the intelligent cloud" is a must view video. This is from AzureCon 2015, September 29, 2015 I have reproduced some screen shots in case you are unable to view this long video for one reason or another. One of the highlights is 3 datacenters coming on line in India.
Oct. 6, 2015 02:00 PM EDT Reads: 226
“The Internet of Things transforms the way organizations leverage machine data and gain insights from it,” noted Splunk’s CTO Snehal Antani, as Splunk announced accelerated momentum in Industrial Data and the IoT. The trend is driven by Splunk’s continued investment in its products and partner ecosystem as well as the creativity of customers and the flexibility to deploy Splunk IoT solutions as software, cloud services or in a hybrid environment. Customers are using Splunk® solutions to collect and correlate data from control systems, sensors, mobile devices and IT systems for a variety of Ind...
Oct. 6, 2015 01:00 PM EDT Reads: 580
SYS-CON Events announced today that ProfitBricks, the provider of painless cloud infrastructure, will exhibit at SYS-CON's 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. ProfitBricks is the IaaS provider that offers a painless cloud experience for all IT users, with no learning curve. ProfitBricks boasts flexible cloud servers and networking, an integrated Data Center Designer tool for visual control over the cloud and the best price/performance value available. ProfitBricks was named one of the coolest Clo...
Oct. 6, 2015 01:00 PM EDT Reads: 737
You have your devices and your data, but what about the rest of your Internet of Things story? Two popular classes of technologies that nicely handle the Big Data analytics for Internet of Things are Apache Hadoop and NoSQL. Hadoop is designed for parallelizing analytical work across many servers and is ideal for the massive data volumes you create with IoT devices. NoSQL databases such as Apache HBase are ideal for storing and retrieving IoT data as “time series data.”
Oct. 6, 2015 12:45 PM EDT Reads: 456
Clearly the way forward is to move to cloud be it bare metal, VMs or containers. One aspect of the current public clouds that is slowing this cloud migration is cloud lock-in. Every cloud vendor is trying to make it very difficult to move out once a customer has chosen their cloud. In his session at 17th Cloud Expo, Naveen Nimmu, CEO of Clouber, Inc., will advocate that making the inter-cloud migration as simple as changing airlines would help the entire industry to quickly adopt the cloud without worrying about any lock-in fears. In fact by having standard APIs for IaaS would help PaaS expl...
Oct. 6, 2015 12:30 PM EDT Reads: 577
Organizations already struggle with the simple collection of data resulting from the proliferation of IoT, lacking the right infrastructure to manage it. They can't only rely on the cloud to collect and utilize this data because many applications still require dedicated infrastructure for security, redundancy, performance, etc. In his session at 17th Cloud Expo, Emil Sayegh, CEO of Codero Hosting, will discuss how in order to resolve the inherent issues, companies need to combine dedicated and cloud solutions through hybrid hosting – a sustainable solution for the data required to manage I...
Oct. 6, 2015 12:00 PM EDT Reads: 438
Apps and devices shouldn't stop working when there's limited or no network connectivity. Learn how to bring data stored in a cloud database to the edge of the network (and back again) whenever an Internet connection is available. In his session at 17th Cloud Expo, Bradley Holt, Developer Advocate at IBM Cloud Data Services, will demonstrate techniques for replicating cloud databases with devices in order to build offline-first mobile or Internet of Things (IoT) apps that can provide a better, faster user experience, both offline and online. The focus of this talk will be on IBM Cloudant, Apa...
Oct. 6, 2015 10:45 AM EDT Reads: 451
Mobile messaging has been a popular communication channel for more than 20 years. Finnish engineer Matti Makkonen invented the idea for SMS (Short Message Service) in 1984, making his vision a reality on December 3, 1992 by sending the first message ("Happy Christmas") from a PC to a cell phone. Since then, the technology has evolved immensely, from both a technology standpoint, and in our everyday uses for it. Originally used for person-to-person (P2P) communication, i.e., Sally sends a text message to Betty – mobile messaging now offers tremendous value to businesses for customer and empl...
Oct. 6, 2015 10:45 AM EDT Reads: 163
As more and more data is generated from a variety of connected devices, the need to get insights from this data and predict future behavior and trends is increasingly essential for businesses. Real-time stream processing is needed in a variety of different industries such as Manufacturing, Oil and Gas, Automobile, Finance, Online Retail, Smart Grids, and Healthcare. Azure Stream Analytics is a fully managed distributed stream computation service that provides low latency, scalable processing of streaming data in the cloud with an enterprise grade SLA. It features built-in integration with Azur...
Oct. 6, 2015 10:00 AM EDT Reads: 732
SYS-CON Events announced today that HPM Networks will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. For 20 years, HPM Networks has been integrating technology solutions that solve complex business challenges. HPM Networks has designed solutions for both SMB and enterprise customers throughout the San Francisco Bay Area.
Oct. 6, 2015 09:00 AM EDT Reads: 568
The enterprise is being consumerized, and the consumer is being enterprised. Moore's Law does not matter anymore, the future belongs to business virtualization powered by invisible service architecture, powered by hyperscale and hyperconvergence, and facilitated by vertical streaming and horizontal scaling and consolidation. Both buyers and sellers want instant results, and from paperwork to paperless to mindless is the ultimate goal for any seamless transaction. The sweetest sweet spot in innovation is automation. The most painful pain point for any business is the mismatch between supplies a...
Oct. 6, 2015 09:00 AM EDT Reads: 136
The broad selection of hardware, the rapid evolution of operating systems and the time-to-market for mobile apps has been so rapid that new challenges for developers and engineers arise every day. Security, testing, hosting, and other metrics have to be considered through the process. In his session at Big Data Expo, Walter Maguire, Chief Field Technologist, HP Big Data Group, at Hewlett-Packard, will discuss the challenges faced by developers and a composite Big Data applications builder, focusing on how to help solve the problems that developers are continuously battling.
Oct. 6, 2015 04:00 AM EDT Reads: 409
SYS-CON Events announced today that IBM Cloud Data Services has been named “Bronze Sponsor” of SYS-CON's 17th Cloud Expo, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. IBM Cloud Data Services offers a portfolio of integrated, best-of-breed cloud data services for developers focused on mobile computing and analytics use cases.
Oct. 5, 2015 11:00 PM EDT Reads: 616
As enterprises capture more and more data of all types – structured, semi-structured, and unstructured – data discovery requirements for business intelligence (BI), Big Data, and predictive analytics initiatives grow more complex. A company’s ability to become data-driven and compete on analytics depends on the speed with which it can provision their analytics applications with all relevant information. The task of finding data has traditionally resided with IT, but now organizations increasingly turn towards data source discovery tools to find the right data, in context, for business users, d...
Oct. 5, 2015 08:00 AM EDT Reads: 378
SYS-CON Events announced today that MobiDev, a software development company, will exhibit at the 17th International Cloud Expo®, which will take place November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. MobiDev is a software development company with representative offices in Atlanta (US), Sheffield (UK) and Würzburg (Germany); and development centers in Ukraine. Since 2009 it has grown from a small group of passionate engineers and business managers to a full-scale mobile software company with over 150 developers, designers, quality assurance engineers, project manage...
Oct. 5, 2015 05:00 AM EDT Reads: 734
Learn how IoT, cloud, social networks and last but not least, humans, can be integrated into a seamless integration of cooperative organisms both cybernetic and biological. This has been enabled by recent advances in IoT device capabilities, messaging frameworks, presence and collaboration services, where devices can share information and make independent and human assisted decisions based upon social status from other entities. In his session at @ThingsExpo, Michael Heydt, founder of Seamless Thingies, will discuss and demonstrate how devices and humans can be integrated from a simple clust...
Oct. 4, 2015 12:00 PM EDT Reads: 628
SYS-CON Events announced today that Cloud Raxak has been named “Media & Session Sponsor” of SYS-CON's 17th Cloud Expo, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Raxak Protect automates security compliance across private and public clouds. Using the SaaS tool or managed service, developers can deploy cloud apps quickly, cost-effectively, and without error.
Oct. 3, 2015 01:15 PM EDT Reads: 624
Who are you? How do you introduce yourself? Do you use a name, or do you greet a friend by the last four digits of his social security number? Assuming you don’t, why are we content to associate our identity with 10 random digits assigned by our phone company? Identity is an issue that affects everyone, but as individuals we don’t spend a lot of time thinking about it. In his session at @ThingsExpo, Ben Klang, Founder & President of Mojo Lingo, will discuss the impact of technology on identity. Should we federate, or not? How should identity be secured? Who owns the identity? How is identity ...
Oct. 3, 2015 11:00 AM EDT Reads: 418